In 1980, Sarepta Therapeutics was founded originally as AVI BioPharma. Today, Sarepta is on an urgent mission: engineer precision genetic medicine for rare diseases that devastate lives and cut futures short.

The company has leadership positions in Duchenne muscular dystrophy (DMD) and limb-girdle muscular dystrophies (LGMDs), and have more than 40 programs in various stages of development.  Their pipeline is driven by our multi-platform Precision Genetic Medicine Engine in gene therapy, RNA and gene editing.